These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

895 related articles for article (PubMed ID: 17663639)

  • 1. Imatinib promotes osteoblast differentiation by inhibiting PDGFR signaling and inhibits osteoclastogenesis by both direct and stromal cell-dependent mechanisms.
    O'Sullivan S; Naot D; Callon K; Porteous F; Horne A; Wattie D; Watson M; Cornish J; Browett P; Grey A
    J Bone Miner Res; 2007 Nov; 22(11):1679-89. PubMed ID: 17663639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The skeletal effects of the tyrosine kinase inhibitor nilotinib.
    O'Sullivan S; Lin JM; Watson M; Callon K; Tong PC; Naot D; Horne A; Aati O; Porteous F; Gamble G; Cornish J; Browett P; Grey A
    Bone; 2011 Aug; 49(2):281-9. PubMed ID: 21550432
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Secreted frizzled-related protein-1 inhibits RANKL-dependent osteoclast formation.
    Häusler KD; Horwood NJ; Chuman Y; Fisher JL; Ellis J; Martin TJ; Rubin JS; Gillespie MT
    J Bone Miner Res; 2004 Nov; 19(11):1873-81. PubMed ID: 15476588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Actions of fibroblast growth factor-8 in bone cells in vitro.
    Lin JM; Callon KE; Lin JS; Watson M; Empson V; Tong PC; Grey A; Naot D; Green CR; Reid IR; Cornish J
    Am J Physiol Endocrinol Metab; 2009 Jul; 297(1):E142-50. PubMed ID: 19383871
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Imatinib mesylate (Gleevec) enhances mature osteoclast apoptosis and suppresses osteoclast bone resorbing activity.
    El Hajj Dib I; Gallet M; Mentaverri R; Sévenet N; Brazier M; Kamel S
    Eur J Pharmacol; 2006 Dec; 551(1-3):27-33. PubMed ID: 17049513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostaglandin E2 stimulates osteoclast-like cell formation and bone-resorbing activity via osteoblasts: role of cAMP-dependent protein kinase.
    Kaji H; Sugimoto T; Kanatani M; Fukase M; Kumegawa M; Chihara K
    J Bone Miner Res; 1996 Jan; 11(1):62-71. PubMed ID: 8770698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Downregulation of osteoblast markers and induction of the glial fibrillary acidic protein by oncostatin M in osteosarcoma cells require PKCdelta and STAT3.
    Chipoy C; Berreur M; Couillaud S; Pradal G; Vallette F; Colombeix C; Rédini F; Heymann D; Blanchard F
    J Bone Miner Res; 2004 Nov; 19(11):1850-61. PubMed ID: 15476586
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epigallocatechin-3-gallate inhibits osteoclastogenesis by down-regulating c-Fos expression and suppressing the nuclear factor-kappaB signal.
    Lee JH; Jin H; Shim HE; Kim HN; Ha H; Lee ZH
    Mol Pharmacol; 2010 Jan; 77(1):17-25. PubMed ID: 19828731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of geranylgeranoic acid in bone: induction of osteoblast differentiation and inhibition of osteoclast formation.
    Wang X; Wu J; Shidoji Y; Muto Y; Ohishi N; Yagi K; Ikegami S; Shinki T; Udagawa N; Suda T; Ishimi Y
    J Bone Miner Res; 2002 Jan; 17(1):91-100. PubMed ID: 11771673
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway.
    Luo XH; Guo LJ; Xie H; Yuan LQ; Wu XP; Zhou HD; Liao EY
    J Bone Miner Res; 2006 Oct; 21(10):1648-56. PubMed ID: 16995820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib mesylate does not increase bone volume in vivo.
    O'Sullivan S; Naot D; Callon KE; Watson M; Gamble GD; Ladefoged M; Karsdal MA; Browett P; Cornish J; Grey A
    Calcif Tissue Int; 2011 Jan; 88(1):16-22. PubMed ID: 20978751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S; Brama M; Mariani S; De Luca G; Arizzi M; Vesci L; Pisano C; Dolci S; Spera G; Gnessi L
    Cancer Res; 2005 Mar; 65(5):1897-903. PubMed ID: 15753388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Regulation of osteoclastogenesis by gap junction communication.
    Matemba SF; Lie A; Ransjö M
    J Cell Biochem; 2006 Oct; 99(2):528-37. PubMed ID: 16639710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imatinib mesylate radiosensitizes human glioblastoma cells through inhibition of platelet-derived growth factor receptor.
    Holdhoff M; Kreuzer KA; Appelt C; Scholz R; Na IK; Hildebrandt B; Riess H; Jordan A; Schmidt CA; Van Etten RA; Dörken B; le Coutre P
    Blood Cells Mol Dis; 2005; 34(2):181-5. PubMed ID: 15727903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transforming growth factor-beta1 increases mRNA levels of osteoclastogenesis inhibitory factor in osteoblastic/stromal cells and inhibits the survival of murine osteoclast-like cells.
    Murakami T; Yamamoto M; Ono K; Nishikawa M; Nagata N; Motoyoshi K; Akatsu T
    Biochem Biophys Res Commun; 1998 Nov; 252(3):747-52. PubMed ID: 9837778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. TNF-alpha mediates p38 MAP kinase activation and negatively regulates bone formation at the injured growth plate in rats.
    Zhou FH; Foster BK; Zhou XF; Cowin AJ; Xian CJ
    J Bone Miner Res; 2006 Jul; 21(7):1075-88. PubMed ID: 16813528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular and molecular effects of growth hormone and estrogen on human bone cells.
    Kassem M
    APMIS Suppl; 1997; 71():1-30. PubMed ID: 9357492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoblast-conditioned medium promotes proliferation and sensitizes breast cancer cells to imatinib treatment.
    Brama M; Basciani S; Cherubini S; Mariani S; Migliaccio S; Arizzi M; Rosano G; Spera G; Gnessi L
    Endocr Relat Cancer; 2007 Mar; 14(1):61-72. PubMed ID: 17395975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
    Slomovitz BM; Broaddus RR; Schmandt R; Wu W; Oh JC; Ramondetta LM; Burke TW; Gershenson DM; Lu KH
    Gynecol Oncol; 2004 Oct; 95(1):32-6. PubMed ID: 15385107
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of imatinib and vinorelbine enhances cell growth inhibition in breast cancer cells via PDGFR beta signalling.
    Weigel MT; Meinhold-Heerlein I; Bauerschlag DO; Schem C; Bauer M; Jonat W; Maass N; Mundhenke C
    Cancer Lett; 2009 Jan; 273(1):70-9. PubMed ID: 18809244
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.